S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Income Expert and Author of Get Rich With Dividends Is Giving Away His Top Income Secrets… FOR FREE! (Ad)
Applied Materials stock is Ray Dalio's favorite in this new cycle
Palo Alto Networks aims at cyber security leadership
Income Expert and Author of Get Rich With Dividends Is Giving Away His Top Income Secrets… FOR FREE! (Ad)
Spotify sounding better to analysts as company tunes into profits
3 Reasons the Capital One-Discover merger is a big deal
Income Expert and Author of Get Rich With Dividends Is Giving Away His Top Income Secrets… FOR FREE! (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Bears covered shorts on this ETF, 3 stocks to pop on the shift
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Income Expert and Author of Get Rich With Dividends Is Giving Away His Top Income Secrets… FOR FREE! (Ad)
Applied Materials stock is Ray Dalio's favorite in this new cycle
Palo Alto Networks aims at cyber security leadership
Income Expert and Author of Get Rich With Dividends Is Giving Away His Top Income Secrets… FOR FREE! (Ad)
Spotify sounding better to analysts as company tunes into profits
3 Reasons the Capital One-Discover merger is a big deal
Income Expert and Author of Get Rich With Dividends Is Giving Away His Top Income Secrets… FOR FREE! (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Bears covered shorts on this ETF, 3 stocks to pop on the shift
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Income Expert and Author of Get Rich With Dividends Is Giving Away His Top Income Secrets… FOR FREE! (Ad)
Applied Materials stock is Ray Dalio's favorite in this new cycle
Palo Alto Networks aims at cyber security leadership
Income Expert and Author of Get Rich With Dividends Is Giving Away His Top Income Secrets… FOR FREE! (Ad)
Spotify sounding better to analysts as company tunes into profits
3 Reasons the Capital One-Discover merger is a big deal
Income Expert and Author of Get Rich With Dividends Is Giving Away His Top Income Secrets… FOR FREE! (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Bears covered shorts on this ETF, 3 stocks to pop on the shift
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Income Expert and Author of Get Rich With Dividends Is Giving Away His Top Income Secrets… FOR FREE! (Ad)
Applied Materials stock is Ray Dalio's favorite in this new cycle
Palo Alto Networks aims at cyber security leadership
Income Expert and Author of Get Rich With Dividends Is Giving Away His Top Income Secrets… FOR FREE! (Ad)
Spotify sounding better to analysts as company tunes into profits
3 Reasons the Capital One-Discover merger is a big deal
Income Expert and Author of Get Rich With Dividends Is Giving Away His Top Income Secrets… FOR FREE! (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Bears covered shorts on this ETF, 3 stocks to pop on the shift
LON:AZN

AstraZeneca (AZN) Share Price, News & Analysis

GBX 9,937
-165.00 (-1.63%)
(As of 04:29 AM ET)
Today's Range
9,908
£100.30
50-Day Range
9,501
£109.02
52-Week Range
9,461
£123.92
Volume
161,494 shs
Average Volume
2.05 million shs
Market Capitalization
£154.02 billion
P/E Ratio
3,290.40
Dividend Yield
2.29%
Price Target
£119

AstraZeneca MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.60 Rating Score
Upside/​Downside
17.8% Upside
£119 Price Target
Short Interest
N/A
Dividend Strength
Weak
Based on Four Factors
Sustainability
-2.35
Upright™ Environmental Score
News Sentiment
0.27mentions of AstraZeneca in the last 14 days
Based on 13 Articles This Week
Insider Trading
Acquiring Shares
£15.13 M Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.44 out of 5 stars


AZN stock logo

About AstraZeneca Stock (LON:AZN)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, andcommercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. Its marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; and Personalis, Inc, as well as research collaboration with Sernova Corp. to evaluate novel potential therapeutic cell applications; and collaboration with Cholesgen (Shanghai) Co.Ltd. to advance research and development in hypercholesterolemia and related metabolic diseases, as well as a collaboration with BioCity Biopharma to evaluate a monoclonal antibody for the treatment of advanced hepatocellular carcinoma and a collaboration agreement with Cellectis. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

AZN Stock Price History

AZN Stock News Headlines

The Gold Story No One's Telling
Gold research firm says we could see much higher gold in 2024. "We'll show you the best possible way to play the current surge in gold for just $5." 
AZN Oct 2024 62.500 put
Analysts Set AstraZeneca PLC (LON:AZN) PT at £122.75
The Gold Story No One's Telling
Gold research firm says we could see much higher gold in 2024. "We'll show you the best possible way to play the current surge in gold for just $5." 
AZN Feb 2024 69.000 call
AstraZeneca (LON:AZN) PT Lowered to GBX 9,900 at UBS Group
Leerink Partners Reaffirms Their Buy Rating on AstraZeneca (AZN)
See More Headlines
Receive AZN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AstraZeneca and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
2/21/2024
Ex-Dividend for 3/25 Dividend
2/22/2024
Dividend Payable
3/25/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Drug Manufacturers - General
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
83,500
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
£119
High Stock Price Target
£135
Low Stock Price Target
GBX 9,900
Potential Upside/Downside
+17.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
10 Analysts

Profitability

Net Income
£5.95 billion
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£45.81 billion
Cash Flow
GBX 259.75 per share
Book Value
GBX 2,527 per share

Miscellaneous

Outstanding Shares
1,550,000,000
Free Float
N/A
Market Cap
£156.58 billion
Optionable
Not Optionable
Beta
0.19
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Mr. Pascal Soriot D.V.M. (Age 65)
    M.B.A., CEO & Executive Director
    Comp: $4.78M
  • Dr. Aradhana Sarin M.D. (Age 49)
    CFO & Executive Director
    Comp: $2.73M
  • Ms. Pam P. Cheng (Age 53)
    EVP of Global opt. & IT, Chief Sust. Officer and Member of External Sust.Adv. Board
  • Mr. Andrew P. Barnett
    Head of Investor Relations
  • Mr. Jeffrey Pott
    CHRO, Chief Compliance Officer, General Counsel & Member of External Sustainability Advisory Board
  • Gonzalo Vina
    Head of Global Media Relations
  • Dr. Menelas Nicolas Pangalos Ph.D. (Age 56)
    EVP of BioPharmaceuticals R&D and Member of External Sustainability Advisory Board
  • Dr. Ruud Dobber Ph.D.
    Executive Vice-President of BioPharmaceuticals Business Unit
  • Dr. Susan Mary Galbraith M.D. (Age 58)
    Ph.D., Executive Vice President of Oncology Research & Development
  • Mr. Leon Wang
    Executive VP of International & China President

Should I Buy AstraZeneca Stock? AZN Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of AstraZeneca was last updated on Wednesday, February 21, 2024 at 1:25 PM.

Pros

Here are some ways that investors could benefit from investing in AstraZeneca PLC:

  • AstraZeneca PLC focuses on the discovery, development, manufacture, and commercialization of prescription medicines, which can lead to potential breakthroughs in the healthcare industry.
  • The company has a strong track record of innovation and research, which can result in the development of new and successful drugs.
  • AstraZeneca PLC has a diverse portfolio of products in various therapeutic areas, reducing the risk associated with relying on a single product.
  • Recent developments have shown positive growth in the company's stock price, indicating potential profitability for investors.
  • AstraZeneca PLC has a solid financial standing with strong net margins and return on equity, providing stability and potential returns for investors.

Cons

Investors should be bearish about investing in AstraZeneca PLC for these reasons:

  • While the company has a diverse product portfolio, it also faces competition from other pharmaceutical companies, which can impact its market share and profitability.
  • AstraZeneca PLC operates in a highly regulated industry, which can lead to challenges in product development and approval processes.
  • There may be risks associated with investing in the pharmaceutical sector, such as regulatory changes, patent expirations, and market volatility.
  • Investors should consider the company's debt-to-equity ratio and other financial metrics to assess its financial health and risk profile.
  • Market conditions and external factors can influence AstraZeneca PLC's performance, so investors should conduct thorough research and analysis before making investment decisions.














AZN Stock Analysis - Frequently Asked Questions

Should I buy or sell AstraZeneca stock right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last year. There are currently 1 sell rating, 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" AZN shares.
View AZN analyst ratings
or view top-rated stocks.

What is AstraZeneca's stock price target for 2024?

10 Wall Street analysts have issued 1 year target prices for AstraZeneca's shares. Their AZN share price targets range from GBX 9,900 to £135. On average, they predict the company's stock price to reach £119 in the next twelve months. This suggests a possible upside of 17.8% from the stock's current price.
View analysts price targets for AZN
or view top-rated stocks among Wall Street analysts.

How have AZN shares performed in 2024?

AstraZeneca's stock was trading at £106 at the beginning of 2024. Since then, AZN stock has decreased by 4.7% and is now trading at £101.02.
View the best growth stocks for 2024 here
.

How often does AstraZeneca pay dividends? What is the dividend yield for AstraZeneca?

AstraZeneca announced a dividend on Thursday, February 8th. Investors of record on Thursday, February 22nd will be given a dividend of GBX 156 per share on Monday, March 25th. This represents a dividend yield of 1.49%. The ex-dividend date is Thursday, February 22nd. This is an increase from the stock's previous dividend of GBX 71.80. The official announcement can be accessed at this link.
Read our dividend analysis for AZN
.

Is AstraZeneca a good dividend stock?

AstraZeneca (LON:AZN) pays an annual dividend of GBX 228 per share and currently has a dividend yield of 2.33%. The dividend payout ratio is 7,549.67%. Payout ratios above 75% are not desirable because they may not be sustainable.
Read our dividend analysis for AZN.

What other stocks do shareholders of AstraZeneca own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AstraZeneca investors own include GSK (GSK), NVIDIA (NVDA), Gilead Sciences (GILD), Intel (INTC), Vodafone Group Public (VOD), Advanced Micro Devices (AMD), Alibaba Group (BABA), Pfizer (PFE), QUALCOMM (QCOM) and The Hain Celestial Group (HAIN).

How do I buy shares of AstraZeneca?

Shares of AZN stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:AZN) was last updated on 2/22/2024 by MarketBeat.com Staff